Petmed Express (NASDAQ:PETS) Lowered to “Sell” at ValuEngine

ValuEngine lowered shares of Petmed Express (NASDAQ:PETS) from a hold rating to a sell rating in a research note published on Wednesday morning, ValuEngine reports.

A number of other analysts have also recently weighed in on PETS. TheStreet raised Petmed Express from a c rating to a b- rating in a research report on Tuesday, October 22nd. Sidoti reissued a buy rating and set a $29.00 price objective on shares of Petmed Express in a report on Thursday, January 2nd. Craig Hallum raised their price objective on Petmed Express from $15.00 to $20.00 and gave the company a hold rating in a research note on Thursday, October 17th. Finally, BidaskClub lowered Petmed Express from a buy rating to a hold rating in a report on Saturday, November 30th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $24.50.

NASDAQ PETS traded down $0.56 during trading on Wednesday, reaching $26.16. The company’s stock had a trading volume of 22,324 shares, compared to its average volume of 398,593. The stock has a market capitalization of $542.50 million, a PE ratio of 20.84 and a beta of 0.62. Petmed Express has a 1-year low of $15.00 and a 1-year high of $27.80. The business has a 50-day moving average price of $23.30 and a 200-day moving average price of $19.70.

Petmed Express (NASDAQ:PETS) last announced its quarterly earnings results on Monday, October 21st. The company reported $0.33 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.07. The company had revenue of $69.94 million for the quarter, compared to analyst estimates of $69.65 million. Petmed Express had a net margin of 9.62% and a return on equity of 20.45%. Petmed Express’s quarterly revenue was down 2.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.52 EPS.

In related news, Director Gian Fulgoni sold 12,000 shares of the company’s stock in a transaction on Wednesday, October 23rd. The shares were sold at an average price of $26.45, for a total transaction of $317,400.00. Following the completion of the sale, the director now directly owns 58,900 shares of the company’s stock, valued at approximately $1,557,905. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 4.00% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of PETS. Quadrant Capital Group LLC lifted its position in shares of Petmed Express by 3,992.3% during the 3rd quarter. Quadrant Capital Group LLC now owns 1,596 shares of the company’s stock worth $28,000 after purchasing an additional 1,557 shares during the last quarter. Tower Research Capital LLC TRC acquired a new position in shares of Petmed Express during the third quarter worth approximately $30,000. FMR LLC boosted its position in shares of Petmed Express by 9,448.1% in the first quarter. FMR LLC now owns 5,156 shares of the company’s stock valued at $118,000 after acquiring an additional 5,102 shares during the period. Bank of Montreal Can boosted its position in shares of Petmed Express by 33.5% in the second quarter. Bank of Montreal Can now owns 8,991 shares of the company’s stock valued at $141,000 after acquiring an additional 2,258 shares during the period. Finally, Pacer Advisors Inc. grew its stake in shares of Petmed Express by 44.8% in the second quarter. Pacer Advisors Inc. now owns 9,695 shares of the company’s stock worth $152,000 after acquiring an additional 2,998 shares during the last quarter. 90.73% of the stock is currently owned by institutional investors.

About Petmed Express

PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.

Further Reading: What is a stock buyback?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.